InterMune Gets Ready To Go Commercial With Esbriet Launch In Europe
InterMune plans to launch the first drug for IPF in Europe in September, and has initiated a new Phase III trial with the aim of securing U.S. approval in 2014.
InterMune plans to launch the first drug for IPF in Europe in September, and has initiated a new Phase III trial with the aim of securing U.S. approval in 2014.